Download new nurse - october 2000 - NHS Greater Glasgow and Clyde

Library Network
Multiple Sclerosis
May 08
Current Awareness Bulletin
Most of the following articles are available online via the NHS Scotland eLibrary.
Please use the links where provided and your ATHENS password. A complete list of
available online journals and registration for ATHENS can be found at
http://www.elib.scot.nhs.uk/
If you would like to request print copies of any of the articles please contact your
nearest library or visit the library website for further details.
http://www.nhsggc.org.uk/libraryservices
Please note inter-library requests will only be done for South Glasgow NHS staff.
Please note, the articles you are accessing may be protected by copyright legislation, please
contact your librarian for a copyright declaration form if you are in any doubt. Or, consult the
Copyright Licensing Agency at http://www.cla.co.uk
If you have any questions regarding this or any other library services please contact
your librarian.
Compiled by C. Boulnois
Library Services Manager (South)
NHS Greater Glasgow & Clyde Library Network
Central Library
Southern General Hospital
1345 Govan Rd
G51 4TF
0141 201 2163
[email protected]
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
References
1.
Achten E, Deblaere K. Health technology assessment on the use of magnetic
resonance imaging (MRI) and computed tomography (CT) in the diagnosis of multiple
sclerosis (MS) and clinically isolated syndromes (CIS). Eur J Radiol. 2008; 65(2):211213.
2.
Agosta F, Valsasina P, Caputo D, Stroman PW, Filippi M. Tactile-associated
recruitment of the cervical cord is altered in patients with multiple sclerosis.
Neuroimage. 2008; 39(4):1542-1548.
3.
Agosta F, Valsasina P, Rocca MA, et al. Evidence for enhanced functional activity of
cervical cord in relapsing multiple sclerosis. Magnetic Resonance in Medicine. 2008;
59(5):1035-1042.
4.
Aguirregomozcorta M, Ramio-Torrenta LI, Gich J, Quiles A, Genis D. Paroxysmal
dystonia and pathological laughter as a first manifestation of multiple sclerosis.
Multiple Sclerosis. 2008; 14(2):262-265.
5.
Airo' P, Scarsi M, Rossi M, Mondini M. Onset and enhancement of systemic sclerosis
after treatments for multiple sclerosis. Rheumatol Int. 2008; 28(7):703-707.
6.
Alonso A, Jick SS, Olek MJ, Hernan MA. Incidence of multiple sclerosis in the united
kingdom : Findings from a population-based cohort. J Neurol. 2007; 254(12):17361741.
7.
Arnett P, Smith MM, Barwick FH, Benedict RHB, Ahlstrom BP. Oralmotor slowing in
multiple sclerosis: Relationship to neuropsychological tasks requiring an oral
response. Journal of the International Neuropsychological Society. 2008; 14(3):454462.
8.
Arthur AT, Armati PJ, Bye C, et al. Genes implicated in multiple sclerosis
pathogenesis from consilience of genotyping and expression profiles in relapse and
remission. BMC Medical Genetics. 2008; 9:17.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
9.
Ascherio A, Munger K. Epidemiology of multiple sclerosis: From risk factors to
prevention. Semin Neurol. 2008; 28(1):17-28.
10.
Aupperle RL, Denney DR, Lynch SG, Carlson SE, Sullivan DK. Omega-3 fatty acids
and multiple sclerosis: Relationship to depression. J Behav Med. 2008; 31(2):127135.
11.
Azoulay D, Urshansky N, Karni A. Low and dysregulated BDNF secretion from
immune cells of MS patients is related to reduced neuroprotection. J Neuroimmunol.
2008; 195(1-2):186-193.
12.
Bamer AM, Cetin K, Amtmann D, Bowen JD, Johnson KL. Comparing a self report
questionnaire with physician assessment for determining multiple sclerosis clinical
disease course: A validation study. Multiple Sclerosis. 2007; 13(8):1033-1037.
13.
Barnes F. Care of people with multiple sclerosis in the community setting. Br J
Community Nurs. 2007; 12(12):552.
14.
Bar-Or A. The immunology of multiple sclerosis. Semin Neurol. 2008; 28(1):29-45.
15.
Bar-Or A, Calabresi PAJ, Arnlod D, et al. Rituximab in relapsing-remitting multiple
sclerosis: A 72-week, open-label, phase I trial. Ann Neurol. 2008; 63(3):395-400.
16.
Baum K, O'Leary C, Ferrer FC, et al. Comparison of injection site pain and injection
site reactions in relapsing-remitting multiple sclerosis patients treated with interferon
beta-1a or 1b. Multiple Sclerosis. 2007; 13(9):1153-1160.
17.
Beeney J, Arnett PA. Stress and memory bias interact to predict depression in
multiple sclerosis. Neuropsychology. 2008; 22(1):118-126.
18.
Beer S, Aschbacher B, Manoglou D, Gamper E, Kool J, Kesselring J. Robot-assisted
gait training in multiple sclerosis: A pilot randomized trial. Multiple Sclerosis. 2008;
14(2):231-236.
19.
Boz C, Oger J, Gibbs E, et al. Reduced effectiveness of long-term interferon-beta
treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: A
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
canadian multiple sclerosis clinic-based study. Multiple Sclerosis. 2007; 13(9):11271137.
20.
Braitch M, Nunan R, Niepel G, Edwards LJ, Constantinescu CS. Increased
osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis.
Archives of Neurology. 2008; 65(5):633-635.
21.
Buttmann M, Rieckmann P. Treating multiple sclerosis with monoclonal antibodies.
Expert Review of Neurotherapeutics. 2008; 8(3):433-455.
22.
Cabrera-Gomez JA, Saiz-Hinarejos A, Graus F, et al. Brain magnetic resonance
imaging findings in acute relapses of neuromyelitis optica spectrum disorders. Multiple
Sclerosis. 2008; 14(2):248-251.
23.
Calabrese M, De Stefano N, Atzori M, et al. Extensive cortical inflammation is
associated with epilepsy in multiple sclerosis. J Neurol. 2008; 255(4):581-586.
24.
Ceccarelli A, Rocca MA, Pagani E, et al. The topographical distribution of tissue
injury in benign MS: A 3T multiparametric MRI study. Neuroimage. 2008;
39(4):1499-1509.
25.
Cetin K, Johnson KL, Ehde DM, Kuehn CM, Amtmann D, Kraft GH. Antidepressant
use in multiple sclerosis: Epidemiologic study of a large community sample. Multiple
Sclerosis. 2007; 13(8):1046-1053.
26.
Cetin K, Johnson KL, Ehde DM, Kuehn CM, Amtmann D, Kraft GH. Antidepressant
use in multiple sclerosis: Epidemiologic study of a large community sample. Multiple
Sclerosis. 2007; 13(8):1046-1053.
27.
Christodoulou C, MacAllister WS, McLinskey NA, Krupp LB. Treatment of cognitive
impairment in multiple sclerosis: Is the use of acetylcholinesterase inhibitors a viable
option? CNS Drugs. 2008; 22(2):87-97.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
28.
Ciccone A, Beretta S, Brusaferri F, Galea I, Protti A, Spreafico C. Corticosteroids for
the long-term treatment in multiple sclerosis. Cochrane Database Syst Rev. 2008;
(1).
29.
Cocco E, Marchi P, Sardu C, et al. Mitoxantrone treatment in patients with early
relapsing-remitting multiple sclerosis. Multiple Sclerosis. 2007; 13(8):975-980.
30.
Correale J, Villa A. Isolation and characterization of CD8+ regulatory T cells in
multiple sclerosis. J Neuroimmunol. 2008; 195(1-2):121-134.
31.
Costelloe L, O'Rourke K, McGuigan C, Walsh C, Tubridy N, Hutchinson M. The
longitudinal relationship between the patient-reported multiple sclerosis impact scale
and the clinician-assessed multiple sclerosis functional composite. Multiple Sclerosis.
2008; 14(2):255-258.
32.
Couturier N, Zappulla JP, Lauwers-Cances V, et al. Mast cell transcripts are
increased within and outside multiple sclerosis lesions. J Neuroimmunol. 2008; 195(12):176-185.
33.
Daumer M, Held U, Ickstadt K, Heinz M, Schach S, Ebers G. Reducing the probability
of false positive research findings by pre-publication validation - experience with a
large multiple sclerosis database. BMC Medical Research Methodology. 2008; 8:18.
34.
Dawson DM. Benign multiple sclerosis: Some recent ideas. Current Neurology &
Neuroscience Reports. 2008; 8(1):1-4.
35.
De las Heras V, De Andres C, Tellez N, et al. Pregnancy in multiple sclerosis patients
treated with immunomodulators prior to or during part of the pregnancy: A
descriptive study in the spanish population. Multiple Sclerosis. 2007; 13(8):981-984.
36.
de Seze M, Ruffion A, Denys P, Joseph P-, Perrouin-Verbe B. The neurogenic bladder
in multiple sclerosis: Review of the literature and proposal of management guidelines.
Multiple Sclerosis. 2007; 13(7):915-928.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
37.
De Stefano N, Filippi M, Hawkins C, 9011 Study G. Short-term combination of
glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone
assessed by MRI-disease activity in patients with relapsing-remitting multiple
sclerosis. J Neurol Sci. 2008; 266(1-2):44-50.
38.
Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F. Validity of a french version
of the fatigue impact scale in multiple sclerosis. Multiple Sclerosis. 2007; 13(8):10261032.
39.
Debouverie M, Pittion-Vouyovitch S, Louis S, Roederer T, Guillemin F. Increasing
incidence of multiple sclerosis among women in lorraine, eastern france. Multiple
Sclerosis. 2007; 13(8):962-967.
40.
Deleu D. Cerebrospinal fluid oligoclonal bands and progression of disability of
multiple sclerosis. European Journal of Neurology. 2008; 15(4):e23.
41.
Duan Y, Hildenbrand PG, Sampat MP, et al. Segmentation of subtraction images for
the measurement of lesion change in multiple sclerosis. Ajnr: American Journal of
Neuroradiology. 2008; 29(2):340-346.
42.
Duquin JA, Parmenter BA, Benedict RHB. Influence of recruitment and participation
bias in neuropsychological research among MS patients. Journal of the International
Neuropsychological Society. 2008; 14(3):494-498.
43.
Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of interferon beta
products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. J
Neurol. 2007; 254(12):1723-1728.
44.
Farrell JAD, Smith SA, Gordon-Lipkin EM, Reich DS, Calabresi PA, Van Zijl PCM. High
b-value q-space diffusion-weighted MRI of the human cervical spinal cord in vivo:
Feasibility and application to multiple sclerosis. Magnetic Resonance in Medicine.
2008; 59(5):1079-1089.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
45.
Farrell R, Kapoor R, Leary S, et al. Neutralizing anti-interferon beta antibodies are
associated with reduced side effects and delayed impact on efficacy of interferonbeta. Multiple Sclerosis. 2008; 14(2):212-218.
46.
Finlayson M, Garcia JD, Preissner K. Development of an educational programme for
caregivers of people aging with multiple sclerosis. Occupational Therapy International.
2008; 15(1):4-17.
47.
Flachenecker P, Meissner H. Fatigue in multiple sclerosis presenting as acute
relapse: Subjective and objective assessment. Multiple Sclerosis. 2008; 14(2):274277.
48.
Flachenecker P, Meissner H. Fatigue in multiple sclerosis presenting as acute
relapse: Subjective and objective assessment. Multiple Sclerosis. 2008; 14(2):274277.
49.
Fox RJ, Lee J-, Rudick RA. Optimal reference population for the multiple sclerosis
functional composite. Multiple Sclerosis. 2007; 13(7):909-914.
50.
Garg N, Weinstock-Guttman B, Bhasi K, Locke J, Ramanathan M. An association
between autoreactive antibodies and anti-interferon-beta antibodies in multiple
sclerosis. Multiple Sclerosis. 2007; 13(7):895-899.
51.
Ghaffar O, Chamelian L, Feinstein A. Neuroanatomy of pseudobulbar affect: A
quantitative MRI study in multiple sclerosis. J Neurol. 2008; 255(3):406-412.
52.
Glanz BI, Holland CM, Gauthier SA, et al. Cognitive dysfunction in patients with
clinically isolated syndromes or newly diagnosed multiple sclerosis. Multiple Sclerosis.
2007; 13(8):1004-1010.
53.
Grapsa E, Triantafyllou N, Rombos A, Lagouranis A, Dimopoulos M-. Therapeutic
plasma exchange combined with immunomodulating agents in secondary progressive
multiple sclerosis patients. Therapeutic Apheresis and Dialysis. 2008; 12(2):105-108.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
54.
Greenberg BM, Calabresi PA. Future research directions in multiple sclerosis
therapies. Semin Neurol. 2008; 28(1):121-127.
55.
Greve B, Simonenko R, Illes Z, et al. Multiple sclerosis and the CTLA4 autoimmunity
polymorphism CT60: No association in patients from germany, hungary and poland.
Multiple Sclerosis. 2008; 14(2):153-158.
56.
Guerrero AL, Martin-Polo J, Laherran E, et al. Variation of serum uric acid levels in
multiple sclerosis during relapses and immunomodulatory treatment. European
Journal of Neurology. 2008; 15(4):394-397.
57.
Haas J, Hommes OR. A dose comparison study of IVIG in postpartum relapsingremitting multiple sclerosis. Multiple Sclerosis. 2007; 13(7):900-908.
58.
Habek M, Brinar VV, Hajnsek S. The association of multiple sclerosis and hodgkin's
disease: The role of epstein-barr virus infection. Multiple Sclerosis. 2008; 14(2):284287.
59.
Hein (nee Maier) K. Kohler A. Diem R. Sattler M.B. Demmer I. Lange P. Bahr M.
Otto M. Biological markers for axonal degeneration in CSF and blood of patients with
the first event indicative for multiple sclerosis. Neurosci Lett. 2008; 436(1):72-76.
60.
Herrera BM, Cader MZ, Dyment DA, et al. Multiple sclerosis susceptibility and the X
chromosome. Multiple Sclerosis. 2007; 13(7):856-864.
61.
Hiestand PC, Rausch M, Meier DP, Foster CA. Ascomycete derivative to MS
therapeutic: S1P receptor modulator FTY720. Progress in Drug Research. 2008;
66:361.
62.
Hoftberger R, Garzuly F, Dienes HP, et al. Fulminant central nervous system
demyelination associated with interferon-alpha therapy and hepatitis C virus infection.
Multiple Sclerosis. 2007; 13(9):1100-1106.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
63.
Holley JE, Newcombe J, Winyard PG, Gutowski NJ. Peroxiredoxin V in multiple
sclerosis lesions: Predominant expression by astrocytes. Multiple Sclerosis. 2007;
13(8):955-961.
64.
Huizinga R, Linington C, Amor S. Resistance is futile: Antineuronal autoimmunity in
multiple sclerosis. Trends Immunol. 2008; 29(2):54-60.
65.
Illes Z, Safrany E, Peterfalvi A, et al. 3'UTR C2370A allele of the IL-23 receptor gene
is associated with relapsing-remitting multiple sclerosis. Neurosci Lett. 2008;
431(1):36-38.
66.
Jeffery DR. Failure of allogeneic bone marrow transplantation to arrest disease
activity in multiple sclerosis. Multiple Sclerosis. 2007; 13(8):1071-1075.
67.
Kabay SC, Yucel M, Kabay S. Acute effect of posterior tibial nerve stimulation on
neurogenic detrusor overactivity in patients with multiple sclerosis: Urodynamic
study. Urology. 2008; 71(4):641-645.
68.
Kantarci OH. Genetics and natural history of multiple sclerosis. Semin Neurol. 2008;
28(1):7-16.
69.
Kern S, Ziemssen T. Brain-immune communication psychoneuroimmunology of
multiple sclerosis. Multiple Sclerosis. 2008; 14(1):6-21.
70.
Kesselring J, Coenen M, Cieza A, Thompson A, Kostanjsek N, Stucki G. Developing
the ICF core sets for multiple sclerosis to specify functioning. Multiple Sclerosis. 2008;
14(2):252-254.
71.
Khayati R, Vafadust M, Towhidkhah F, Nabavi SM. A novel method for automatic
determination of different stages of multiple sclerosis lesions in brain MR FLAIR
images. Computerized Medical Imaging & Graphics. 2008; 32(2):124-133.
72.
Kimiskidis VK, Sakellari I, Tsimourtou V, et al. Autologous stem-cell transplantation
in malignant multiple sclerosis: A case with a favorable long-term outcome. Multiple
Sclerosis. 2008; 14(2):278-283.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
73.
Koch M, Heersema D, Mostert J, Teelken A, De Keyser J. CSF oligoclonal bands and
progression of disability in multiple sclerosis. European Journal of Neurology. 2008;
15(4):e24.
74.
Koch M, Mostert J, Arutjunyan A, et al. Peripheral blood leukocyte NO production
and oxidative stress in multiple sclerosis. Multiple Sclerosis. 2008; 14(2):159-165.
75.
Kolind SH, Laule C, Vavasour IM, et al. Complementary information from multiexponential T2 relaxation and diffusion tensor imaging reveals differences between
multiple sclerosis lesions. Neuroimage. 2008; 40(1):77-85.
76.
Koontz D, Alshekhlee A. Embolia cutis medicamentosa following interferon beta
injection. Multiple Sclerosis. 2007; 13(9):1203-1204.
77.
Kos D, Duportail M, D'hooghe MB, Nagels G, Kerckhofs E. Multidisciplinary fatigue
management programme in multiple sclerosis: A randomized clinical trial. Multiple
Sclerosis. 2007; 13(8):996-1003.
78.
Kumpfel T, Schwan M, Pollmacher T, et al. Time of interferon-beta 1a injection and
duration of treatment affect clinical side effects and acute changes of plasma
hormone and cytokine levels in multiple sclerosis patients. Multiple Sclerosis. 2007;
13(9):1138-1145.
79.
Laule C, Kozlowski P, Leung E, Li DKB, MacKay AL, Moore GRW. Myelin water
imaging of multiple sclerosis at 7 T: Correlations with histopathology. Neuroimage.
2008; 40(4):1575-1580.
80.
Lee D, Newell R, Ziegler L, Topping A. Treatment of fatigue in multiple sclerosis: A
systematic review of the literature. Int J Nurs Pract. 2008; 14(2):81-93.
81.
Lehmann HC, Hartung H-, Kieseier BC. Leopold ordenstein: On paralysis agitans and
multiple sclerosis. Multiple Sclerosis. 2007; 13(9):1195-1199.
82.
Lehmensiek V, Sussmuth SD, Tauscher G, et al. Cerebrospinal fluid proteome profile
in multiple sclerosis. Multiple Sclerosis. 2007; 13(7):840-849.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
83.
Leray E, Morrissey SP, Yaouang J, et al. Long-term survival of patients with multiple
sclerosis in west france. Multiple Sclerosis. 2007; 13(7):865-874.
84.
Lezzoni LI, Ngo LH, Kinkel RP. Working-age persons with multiple sclerosis and
access to disease-modifying medications. Multiple Sclerosis. 2008; 14(1):112-122.
85.
Li XY. Combined application of three evoked potentials to improve the diagnosis of
multiple sclerosis. Neural Regeneration Research. 2006; 1(6):569-572.
86.
Lidegaard O, Svendsen AL. Sexual habits before multiple sclerosis: A national casecontrol study. Multiple Sclerosis. 2008; 14(1):67-72.
87.
Lindsey JW, Patel S. PCR for bacterial 16S ribosomal DNA in multiple sclerosis
cerebrospinal fluid. Multiple Sclerosis. 2008; 14(2):147-152.
88.
Lovrecic L, Ristic S, Starcevic-Cizmarevic N, et al. PAI and TPA gene polymorphisms
in multiple sclerosis. Multiple Sclerosis. 2008; 14(2):243-247.
89.
Lucas RM, Ponsonby A-, McMichael AJ, et al. Observational analytic studies in
multiple sclerosis: Controlling bias through study design and conduct. the australian
multicentre study of environment and immune function. Multiple Sclerosis. 2007;
13(7):827-839.
90.
Lutterotti A, Martin R. Getting specific: Monoclonal antibodies in multiple sclerosis.
Lancet Neurology. 2008; 7(6):538-547.
91.
Malcomson KS, Lowe-Strong AS, Dunwoody L. What can we learn from the personal
insights of individuals living and coping with multiple sclerosis. Disability and
Rehabilitationa. 2008; 30(9):662-674.
92.
Manson SC, Wegner C, Filippi M, et al. Impairment of movement-associated brain
deactivation in multiple sclerosis: Further evidence for a functional pathology of
interhemispheric neuronal inhibition. Experimental Brain Research. 2008; 187(1):2531.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
93.
Marrie RA, Goldman M. Validity of performance scales for disability assessment in
multiple sclerosis. Multiple Sclerosis. 2007; 13(9):1176-1182.
94.
Marrosu F, Maleci A, Cocco E, Puligheddu M, Barberini L, Marrosu MG. Vagal nerve
stimulation improves cerebellar tremor and dysphagia in multiple sclerosis. Multiple
Sclerosis. 2007; 13(9):1200-1202.
95.
Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar S, et al. IL-10 suppressor
activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J
Immunol. 2008; 38(2):576-586.
96.
Massart C, Gibassier J, de Seze J, et al. Determination of interferon beta
neutralizing antibodies in multiple sclerosis: Improvement of clinical sensitivity of a
cytopathic effect assay. Clinica Chimica Acta. 2008; 391(1-2):98-101.
97.
Matesanz F, Fernandez O, Milne RL, et al. The high producer variant of the fcreceptor like-3 (FCRL3) gene is involved in protection against multiple sclerosis. J
Neuroimmunol. 2008; 195(1-2):146-150.
98.
McClurg D, Ashe RG, Lowe-Strong AS. Neuromuscular electrical stimulation and the
treatment of lower urinary tract dysfunction in multiple sclerosis--a double blind,
placebo controlled, randomised clinical trial. Neurourology & Urodynamics. 2008;
27(3):231-237.
99.
Mhaille AN, McQuaid S, Windebank A, et al. Increased expression of endoplasmic
reticulum stress-related signaling pathway molecules in multiple sclerosis lesions. J
Neuropathol Exp Neurol. 2008; 67(3):200-211.
100.
Mikaeloff Y, Caridade G, Tardieu M, Suissa S. Effectiveness of early beta interferon
on the first attack after confirmed multiple sclerosis: A comparative cohort study.
European Journal of Paediatric Neurology. 2008; 12(3):205-209.
101.
Morandi B, Bramanti P, Bonaccorsi I, et al. Role of natural killer cells in the
pathogenesis and progression of multiple sclerosis. Pharmacological Research. 2008;
57(1):1-5.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
102.
Moret-Hartman M, Reuzel R, Grin J, Van Der Wilt GJ. Participatory workshops are
not enough to prevent policy implementation failures: An example of a policy
development process concerning the drug interferon-beta for multiple sclerosis.
Health Care Analysis. 2008; 16(2):161-175.
103.
Motl RW, Snook EM. Physical activity, self-efficacy, and quality of life in multiple
sclerosis. Annals of Behavioral Medicine. 2008; 35(1):111-115.
104.
Moyes DL, Goris A, Ban M, et al. HERV-K113 is not associated with multiple
sclerosis in a large family-based study. AIDS Res Hum Retroviruses. 2008;
24(3):363-365.
105.
Munteis E, Andreu M, Martinez-Rodriguez JE, Ois A, Bory F, Roquer J. Manometric
correlations of anorectal dysfunction and biofeedback outcome in patients with
multiple sclerosis. Multiple Sclerosis. 2008; 14(2):237-242.
106.
Myhr K. Diagnosis and treatmetn of multiple sclerosis. Acta Neurologica
Scandinavica Supplementum. 2008; 117(Suppl 188):12-21.
107.
Newbold D. Finding a more secure financial future for MS. British Journal of
Neuroscience Nursing. 2008; 4(5):239-241.
108.
Newman Wright B, Wilkins AJ, Zoukos Y. Spectral filters can improve reading and
visual search in patients with multiple sclerosis. J Neurol. 2007; 254(12):1729-1735.
109.
Okuyucu EE, Okuyucu S, Karazincir S, Akoglu E, Duman T. Acute 'upside-down'
visual inversion due to multiple sclerosis. Multiple Sclerosis. 2008; 14(2):266-267.
110.
Olsson M, Lexell J, Soderberg S. The meaning of women's experiences of living
with multiple sclerosis. Health Care Women Int. 2008; 29(4):416-430.
111.
Pakenham KI. The nature of caregiving in multiple sclerosis: Development of the
caregiving tasks in multiple sclerosis scale. Multiple Sclerosis. 2007; 13(7):929-938.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
112.
Pampliega O, Domercq M, Villoslada P, Sepulcre J, Rodriguez-Antiguedad A, Matute
C. Association of an EAAT2 polymorphism with higher glutamate concentration in
relapsing multiple sclerosis. J Neuroimmunol. 2008; 195(1-2):194-198.
113.
Patten SB, Newman S, Becker M, Riddell C, Metz L. Disease management for
depression in an MS clinic. Int J Psychiatry Med. 2007; 37(4):459-473.
114.
Peng F, Zhang B, Zhong X, et al. Serum uric acid levels of patients with multiple
sclerosis and other neurological diseases. Multiple Sclerosis. 2008; 14(2):188-196.
115.
Penner I-, Bechtel N, Raselli C, et al. Fatigue in multiple sclerosis: Relation to
depression, physical impairment, personality and action control. Multiple Sclerosis.
2007; 13(9):1161-1167.
116.
Perumal J, Zabad R, Caon C, et al. Acute transverse myelitis with normal brain MRI
: Long-term risk of MS. J Neurol. 2008; 255(1):89-93.
117.
Peterson EW, Cho CC, Finlayson ML. Fear of falling and associated activity
curtailment among middle aged and older adults with multiple sclerosis. Multiple
Sclerosis. 2007; 13(9):1168-1175.
118.
Pietrosi G, Mandala L, Vizzini GB, et al. Fulminant hepatic failure and autoimmune
disorders in patient with multiple sclerosis on interferon beta 1a: A fatal
combination?. Transplant Int. 2008; 21(5):502-504.
119.
Pohlau D, Przuntek H, Sailer M, et al. Intravenous immunoglobulin in primary and
secondary chronic progressive multiple sclerosis: A randomized placebo controlled
multicentre study. Multiple Sclerosis. 2007; 13(9):1107-1117.
120.
Pugliatti M, Harbo HF, Holmy T, et al. Environmental risk factors in multiple
sclerosis. Acta Neurologica Scandinavica Supplementum. 2008; 117(Suppl 188):3440.
121.
Racke MK. The role of B cells in multiple sclerosis: Rationale for B-cell-targeted
therapies. Curr Opin Neurol. 2008; 21(1):S9-S18.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
122.
Ramagopalan SV, Herrera BM, Bell JT, et al. Parental transmission of HLADRB1*15 in multiple sclerosis. Hum Genet. 2008; 122(6):661-663.
123.
Ramkumar B, Chadha MK, Barcos M, Sait SNJ, Heyman MR, Baer MR. Acute
promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis. Cancer
Genet Cytogenet. 2008; 182(2):126-129.
124.
Rashid W, Hadjiprocopis A, Davies G, et al. Longitudinal evaluation of clinically
early relapsing-remitting multiple sclerosis with diffusion tensor imaging. J Neurol.
2008; 255(3):390-397.
125.
Rashid W, Miller DH. Recent advances in neuroimaging of multiple sclerosis. Semin
Neurol. 2008; 28(1):46-55.
126.
Reich DS, Zackowski KM, Gordon-Lipkin EM, et al. Corticospinal tract abnormalities
are associated with weakness in multiple sclerosis. Ajnr: American Journal of
Neuroradiology. 2008; 29(2):333-339.
127.
Roccatogliata L, Rocca MA, Valsasina P, et al. The long-term effect of AHSCT on
MRI measures of MS evolution: A five-year follow-up study. Multiple Sclerosis. 2007;
13(8):1068-1070.
128.
Roosendaal SD, Moraal B, Vrenken H, et al. In vivo MR imaging of hippocampal
lesions in multiple sclerosis. Journal of Magnetic Resonance Imaging. 2008;
27(4):726-731.
129.
Rosti-Otajarvi E, Hamalainen P, Koivisto K, Hokkanen L. The reliability of the MSFC
and its components. Acta Neurologica Scandinavica. 2008; 117(6):421-427.
130.
Ruiz-Pena JL, Duque P, Izquierdo G. Optimization of treatment with interferon beta
in multiple sclerosis. usefulness of automatic system application criteria. BMC
Neurology. 2008; 8:3.
131.
Ruprecht K, Gronen F, Sauter M, Best B, Rieckmann P, Mueller-Lantzsch N. Lack of
immune responses against multiple sclerosis-associated retrovirus/human
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
endogenous retrovirus W in patients with multiple sclerosis. J Neurovirol. 2008;
14(2):143-151.
132.
Sadiq SA, Rammal M, Sara G. Chronic myeloid leukemia associated with
mitoxantrone treatment in a patient with MS. Multiple Sclerosis. 2008; 14(2):272273.
133.
Saito H, Suzuki M, Asakawa T, Kato S. Retinopathy in a multiple sclerosis patient
undergoing interferon-therapy. Multiple Sclerosis. 2007; 13(7):939-940.
134.
Sarchielli P, Di Filippo M, Ercolani MV, et al. Fibroblast growth factor-2 levels are
elevated in the cerebrospinal fluid of multiple sclerosis patients. Neurosci Lett. 2008;
435(3):223-228.
135.
Schmierer K, Wheeler-Kingshott CA, Tozer DJ, et al. Quantitative magnetic
resonance of postmortem multiple sclerosis brain before and after fixation. Magnetic
Resonance in Medicine. 2008; 59(2):268-277.
136.
Schwartzman RJ, Gurusinghe C, Gracely E. Prevalence of complex regional pain
syndrome in a cohort of multiple sclerosis patients. Pain Physician. 2008; 11(2):133136.
137.
Sellner J, Greeve I, Findling O, Grandgirard D, Leib SL, Mattle HP. Atorvastatin
does not alter serum levels of sCD95 and sCD95L in multiple sclerosis. Clin Exp
Immunol. 2008; 152(2):280-284.
138.
Serarslan G, Okuyucu EE, Melek IM, Hakverdi S, Duman T. Widespread
maculopapular rash due to intramuscular interferon beta-1a during the treatment of
multiple sclerosis. Multiple Sclerosis. 2008; 14(2):259-261.
139.
Simeoni MC, Auquier P, Flachenecker P, et al. Validation of the multiple sclerosis
international quality of life questionnaire. Multiple Sclerosis. 2008; 14(2):219-230.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
140.
Sloka JS, Pryse-Phillips WEM, Stefanelli M. The relation of ultraviolet radiation and
multiple sclerosis in newfoundland. Canadian Journal of Neurological Sciences. 2008;
35(1):69-74.
141.
Smestad C, Sandvik L, Holmoy T, Harbo HF, Celius EG. Marked differences in
prevalence of multiple sclerosis between ethnic groups in oslo, norway. J Neurol.
2008; 255(1):49-55.
142.
Sobocki P, Pugliatti M, Lauer K, Kobelt G. Estimation of the cost of MS in europe:
Extrapolations from a multinational cost study. Multiple Sclerosis. 2007; 13(8):10541064.
143.
Solari A, Motta A, Radice D, Mendozzi L. A shortened version of PASAT-3 is
feasible. Multiple Sclerosis. 2007; 13(8):1020-1025.
144.
Soon D, Tozer DJ, Altmann DR, Tofts PS, Miller DH. Quantification of subtle bloodbrain barrier disruption in non-enhancing lesions in multiple sclerosis: A study of
disease and lesion subtypes. Multiple Sclerosis. 2007; 13(7):884-894.
145.
Stinson MD, Crawford SA, Porter-Armstrong AP. Interface pressure measurements;
visual interpretation of pressure maps with MS clients. Disability and Rehabilitation.
2008; 30(8):618-624.
146.
Strasser-Fuchs S, Enzinger C, Ropele S, Wallner M, Fazekas F. Clinically benign
multiple sclerosis despite large T2 lesion load: Can we explain this paradox?. Multiple
Sclerosis. 2008; 14(2):205-211.
147.
Stuve O, Cravens PD, Eagar TN. DNA-based vaccines: The future of multiple
sclerosis therapy?. Expert Review of Neurotherapeutics. 2008; 8(3):351-360.
148.
Summers MM, Fisniku LK, Anderson VM, Miller DH, Cipolotti L, Ron MA. Cognitive
impairment in relapsing-remitting multiple sclerosis can be predicted by imaging
performed several years earlier. Multiple Sclerosis. 2008; 14(2):197-204.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
149.
Sweetland J, Riazi A, Cano SJ, Playford ED. Vocational rehabilitation services for
people with multiple sclerosis: What patients want from clinicians and employers.
Multiple Sclerosis. 2007; 13(9):1183-1189.
150.
Takahashi M, Tsunemi T, Miyayosi T, Mizusawa H. Reversible central neurogenic
hyperventilation in an awake patient with multiple sclerosis. J Neurol. 2007;
254(12):1763-1764.
151.
Thomas T, Banwell B. Multiple sclerosis in children. Semin Neurol. 2008; 28(1):6983.
152.
Thouvenot E, Hillaire-Buys D, Bos-Thompson MA, et al. Erythema nodosum and
glatiramer acetate treatment in relapsing-remitting multiple sclerosis. Multiple
Sclerosis. 2007; 13(7):941-944.
153.
Tomassini V, De Giglio L, Reindl M, et al. Anti-myelin antibodies predict the clinical
outcome after a first episode suggestive of MS. Multiple Sclerosis. 2007; 13(9):10861094.
154.
Townsend G. Supporting people with multiple sclerosis in employment: A united
kingdom survey of current practice and experience. Br J Occup Ther. 2008;
71(3):103-111.
155.
Traboulsee A, Al-Sabbagh A, Bennett R, Chang P, Li DKB. Reduction in magnetic
resonance imaging T2 burden of disease in patients with relapsing-remitting multiple
sclerosis: Analysis of 48-week data from the EVIDENCE (EVidence of interferon doseresponse: European north american comparative efficacy) study. .
156.
Tripoliti E, Campbell C, Pring T, Taylor-Goh S. Quality of life in multiple sclerosis:
Should clinicians trust proxy ratings?. Multiple Sclerosis. 2007; 13(9):1190-1194.
157.
Trojan DA, Arnold D, Collet J-, et al. Fatigue in multiple sclerosis: Association with
disease-related, behavioural and psychosocial factors. Multiple Sclerosis. 2007;
13(8):985-995.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
158.
Turner AP, Kivlahan DR, Sloan AP, Haselkorn JK. Predicting ongoing adherence to
disease modifying therapies in multiple sclerosis: Utility of the health beliefs model.
Multiple Sclerosis. 2007; 13(9):1146-1152.
159.
Turpin KVL, Carroll LJ, Cassidy JD, Hader WJ. Deterioration in the health-related
quality of life of persons with multiple sclerosis: The possible warning signs. Multiple
Sclerosis. 2007; 13(8):1038-1045.
160.
Vaknin-Dembinsky A, Murugaiyan G, Hafler DA, Astier AL, Weiner HL. Increased
IL-23 secretion and altered chemokine production by dendritic cells upon CD46
activation in patients with multiple sclerosis. J Neuroimmunol. 2008; 195(1-2):140145.
161.
van der Linden FA, Kragt JJ, van Bon M, et al. Longitudinal proxy measurements in
multiple sclerosis: Patient-proxy agreement on the impact of MS on daily life over a
period of two years. BMC Neurology. 2008; 8:2.
162.
van Kessel K, Moss-Morris R, Willoughby E, Chalder T, Johnson MH, Robinson E. A
randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue.
Psychosom Med. 2008; 70(2):205-213.
163.
Vavasour IM, Li DK, Laule C, Traboulsee AL, Moore GR, Mackay AL. Multiparametric MR assessment of T(1) black holes in multiple sclerosis : Evidence that
myelin loss is not greater in hypointense versus isointense T(1) lesions. J Neurol.
2007; 254(12):1653-1659.
164.
Villar LM, Garcia-Barragan N, Espino M, et al. Influence of oligoclonal IgM
specificity in multiple sclerosis disease course. Multiple Sclerosis. 2008; 14(2):183187.
165.
Villar LM, Garcia-Barragan N, Sadaba MC, et al. Accuracy of CSF and MRI criteria
for dissemination in space in the diagnosis of multiple sclerosis. J Neurol Sci. 2008;
266(1-2):34-37.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
166.
Vuger-Kovacic D, Gregurek R, Kovacic D, Vuger T, Kalenic B. Relation between
anxiety, depression and locus of control of patients with multiple sclerosis. Multiple
Sclerosis. 2007; 13(8):1065-1067.
167.
Ward-Abel N, Burgoyne T. The importance of the immune response in multiple
sclerosis part 1: Pathophysiology. British Journal of Neuroscience Nursing. 2008;
4(5):212-217.
168.
Wattjes MP, Harzheim M, Lutterbey GG, Bogdanow M, Schild HH, Traber F. High
field MR imaging and 1H-MR spectroscopy in clinically isolated syndromes suggestive
of multiple sclerosis: Correlation between metabolic alterations and diagnostic MR
imaging criteria. J Neurol. 2008; 255(1):56-63.
169.
Weber F, Fontaine B, Cournu-Rebeix I, et al. IL2RA and IL7RA genes confer
susceptibility for multiple sclerosis in two independent european populations. Genes
Immun. 2008; 9(3):259-263.
170.
White LJ, Castellano V. Exercise and brain health--implications for multiple
sclerosis: Part 1--neuronal growth factors. Sports Medicine. 2008; 38(2):91-100.
171.
Wiesemann E, Deb M, Trebst C, Hemmer B, Stangel M, Windhagen A. Effects of
interferon-beta on co-signaling molecules: Upregulation of CD40, CD86 and PD-L2 on
monocytes in relation to clinical response to interferon-beta treatment in patients with
multiple sclerosis. Multiple Sclerosis. 2008; 14(2):166-176.
172.
Wingerchuk DM. Current evidence and therapeutic strategies for multiple sclerosis.
Semin Neurol. 2008; 28(1):56-68.
173.
Woolmore JA, Stone MJ, Holley SL, et al. Polymorphisms of the cannabinoid 1
receptor gene and cognitive impairment in multiple sclerosis. Multiple Sclerosis. 2008;
14(2):177-182.
174.
Younes M, Hill J, Quinless J, et al. Internet-based cognitive testing in multiple
sclerosis. Multiple Sclerosis. 2007; 13(8):1011-1019.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
175.
Young EA, Fowler CD, Kidd GJ, et al. Imaging correlates of decreased axonal
Na+/K+ ATPase in chronic multiple sclerosis lesions. Annals of Neurology. 2008;
63(4):428-435.
176.
Yukitake M, Sueoka E, Sueoka-Aragane N, et al. Significantly increased antibody
response to heterogeneous nuclear ribonucleoproteins in cerebrospinal fluid of
multiple sclerosis patients but not in patients with human T-lymphotropic virus type I
- associated myelopathy/tropical spastic paraparesis. J Neurovirol. 2008; 14(2):130135.
177.
Zhang B, Jiang Y, Yang Y, Peng F, Hu X. Correlation between serum thyroxine and
complements in patients with multiple sclerosis and neuromyelitis optica.
Neuroendocrinol Lett. 2008; 29(2):256-260.
178.
Zhang Y, Zabad RK, Wei X, Metz LM, Hill MD, Mitchell JR. Deep grey matter "black
T2" on 3 tesla magnetic resonance imaging correlates with disability in multiple
sclerosis. Multiple Sclerosis. 2007; 13(7):880-883.
179.
Zipoli V, Portaccio E, Hakiki B, Siracusa G, Sorbi S, Pia Amato M. Intravenous
mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: An
open-label comparative study of efficacy and safety. J Neurol Sci. 2008; 266(1-2):2530.
180.
Zivadinov R, Banas AC, Yella V, Abdelrahman N, Weinstock-Guttman B, Dwyer MG.
Comparison of three different methods for measurement of cervical cord atrophy in
multiple sclerosis. Ajnr: American Journal of Neuroradiology. 2008; 29(2):319-325.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
If you would like to receive additional bulletin, please tick the bulletins you would
like to receive, ensure your name and address are on the front cover and return to
thelibrary address given overleaf.
A&E
Allied Health Professionals
Alzheimer’s disease
Ambulatory care
Anaesthesia
Asthma
Burns/Dermatology/Plastics
Cancer: Pain
Cancer Supportive Care
Chaplain
Child Protection
Clinical Governance
Community Child Health
Community Nursing
Complaints
Coronary Intensive and High Dependency Care
Corporate Services
Day surgery
Dental Care Professionals
Dentistry
Digestive Diseases
Elderly Care Bulletin (Nursing)
Epilepsy
Guidelines
Gynaecologic Oncology
Head Injury
Health Promotion
Healthcare Associated Infection
Healthy Heart
IT
Lung Cancer
Medicine for the Elderly
Multiple Sclerosis
Neonatal Nursing and Midwifery
New Books
New Books (all sites & Nursing)
New Nurse
Nutrition
Orthopaedics
Paediatric Anaesthesia & Pain
Paediatric Oncology Nursing
Paediatric Physiotherapy
Paediatric Respiratory Medicine
Parkinson’s disease
Pharmacy
Prevention & Treatment of Alcohol &
Drug Abuse (Nursing)
Primary Care Mental Health
Rheumatology
Sarcoma
School nurses
Speech and Language Therapy
Spinal Injuries
Stroke (North Glasgow)
Stroke (South Glasgow)
Training, education and Management
(Nursing)
How to Access Electronic Articles
Many of the articles in this bulletin will be available online at the NHS Scotland eLibrary
1.
2.
3.
4.
5.
6.
Go to the NHS Scotland eLibrary http://www.elib.scot.nhs.uk
Click on Journals
Type in the journal title and click search.
Click on the appropriate title, then select the supplier you wish to use.
Put in your Athens password at the “Athens login” link.
Select the correct year, volume, issue and page number for the article you
want.
Please note, the articles you are accessing may be protected by copyright legislation, please
contact your librarian for a copyright declaration form if you are in any doubt. Or, consult the
Copyright Licensing Agency at http://www.cla.co.uk
If you have any questions regarding this or any other library services please contact
your librarian.
Compiled by C. Boulnois
Library Services Manager
NHS Greater Glasgow & Clyde Library Network
Central Library
Southern General Hospital
1345 Govan Rd
Glasgow
G51 4TF
0141 201 2163
[email protected]
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.